Find a Clinical Trial
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
NIAID is committed to advancing the understanding of how and why autoimmune diseases such as rheumatoid arthritis occur.
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children (MUPPITS-2)
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation.
Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma.
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype.
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
There is a need for people to take part in research studies to learn more about diseases and how to treat them.
This will be a single site, mechanistic study of asthmatic subjects and healthy, non-asthmatic controls involving a baseline characterization visit and a research bronchoscopy visit.
Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics (ACE)
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
This study tests the hypothesis that an increase in pathogenic bacteria within the infant airway leads to increased airway inflammation, decreased airway function and ultimately airway obstruction throughout the first one to two years of life.
The primary objective of this study is to further characterize the natural history of idiopathic CD4 lymphocytopenia (ICL) while also investigating the genetic, environmental, and immunologic features of the condition.
Chronic Granulomatous Disease (CGD)
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
To learn more about when and why IBD may develop in some people with primary immune dysregulation.
This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.
To see if RFA is a safe and effective treatment for CGD-related liver abscesses.
This study is a prospective non-controlled, non-randomized Phase I/II clinical trial to assess the safety, feasibility and efficacy of cellular gene therapy in patients with chronic granulomatous disease.
This protocol is designed to study the techniques needed to develop gene therapy or other treatments for certain inherited immune system diseases.
Chronic Granulomatous Disease (CGD) and Hyper-Immunoglobulin M (Hyper-IgM) Syndromes and Primary Immune Deficiency Diseases (PIDDs) and Wiskott-Aldrich Syndrome (WAS) and X-Linked Agammaglobulinemia (XLA) and X-Linked Lymphoproliferative Disease (XLP)
To collect data on people with primary immune deficiency disorders.
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with COVID-19. BET is a proof-of-concept study with the intent of identifying promising treatments to enter a more definitive study. The study will be conducted in up to 40 sites throughout the US. The study will compare different investigational therapeutic agents to a common control arm and determine which have relatively large effects. In order to maintain the double blind, each intervention will have a matched placebo. However, the control arm will be shared between interventions and may include participants receiving the matched placebo for a different intervention.
The goal is not to determine clear statistical significance for an intervention, but rather to determine which products have clinical data suggestive of efficacy and should be moved quickly into larger studies. Estimates produced from BET will provide an improved basis for designing the larger trial, in terms of sample size and endpoint selection. Products with little indication of efficacy will be dropped on the basis of interim evaluations. In addition, some interventions may be discontinued on the basis of interim futility or efficacy analyses.
Cardiopulmonary Inflammation and Multi-System Imaging During COVID-19 Infection in Asymptomatic and Symptomatic Persons
A study to learn how coronavirus affects different organs of the body and the function of the body's immune system.
COVID-19 Antibody Treatment Study for Preventing SARS-CoV-2 Infection in Nursing Home Residents and Staff
This trial will assess whether LY-CoV555, a potential COVID-19 antibody treatment, can prevent SARS-CoV-2 infection among people at high risk of exposure due to residing or working in skilled nursing or assisted living facilities.
The NIAID Vaccine Research Center is looking for volunteers who are fully recovered from confirmed COVID-19 infection to donate blood for a research study. The aim of the study is to further define and understand specific immune responses.
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC.
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. Participants in the study will receive an experimental therapy or a placebo.
This research study is about an experimental drug for COVID-19 called NT-I7. We are studying whether the experimental drug is safe for people with COVID-19. We also want to see if it might help treat COVID-19 by supporting the immune system.